Drug Trial Radar · NCT05245682
Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer
Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
10
Actual
Start
Feb 17, 2022
Primary completion
Jan 15, 2024
Study completion Jul 21, 2027
Sponsor
- Lead sponsor
- Emory UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Astex Pharmaceuticals, Inc.; National Cancer Institute (NCI)
- First posted
- Feb 18, 2022
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This early-phase trial tests the safety and side effects of a tolinapant given together with radiation therapy in treating patients with head and neck cancer for which the patient has not received treatment in the past (previously untreated), has spread to nearby tissue or lymph nodes (locally advanced) and cannot receive cisplatin (cisplatin-ineligible). Tolinapant may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving tolinapant and radiation therapy may kill more tumor cells.
Conditions
- Head and Neck Carcinoma of Unknown Primary
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- Locally Advanced Hypopharyngeal Squamous Cell Carcinoma
- Locally Advanced Laryngeal Squamous Cell Carcinoma
- Locally Advanced Nasopharyngeal Squamous Cell Carcinoma
- Locally Advanced Oropharyngeal Squamous Cell Carcinoma
Interventions
TolinapantDrug
Given PO
Radiation TherapyRadiation
Undergo radiation therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of Tolinapant + Radiation (Number of Patients With Adverse Events Per CTCAE v5.0)Time frame: Up to 60 days post-treatment
- Feasibility of Tolinapant + Radiation (Number of Patients Able to Complete Treatment)Time frame: Upon completion of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Emory University/Winship Cancer Institute
Atlanta, Georgia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.